- CA$4.56m
- CA$3.77m
- CA$3.49m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.83 | ||
| Price to Tang. Book | 1.87 | ||
| Price to Free Cashflow | 12.95 | ||
| Price to Sales | 0.97 | ||
| EV to EBITDA | 6.43 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 4.67% | ||
| Return on Equity | 4.8% | ||
| Operating Margin | 2.46% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CA$m | 0.03 | 0.03 | 0.12 | 1.77 | 3.49 | n/a | n/a | 196.15% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Avricore Health Inc. is a pharmacy service innovator focused on acquiring and developing early-stage technologies aimed at advancing pharmacy practice and patient care. The Company is involved in the business of health data and point-of-care technologies (POCT). HealthTab, its flagship offering, is a turnkey point-of-care testing solution that combines point-of-care technologies with a secure, cloud-based platform for tackling pressing global health issues. With just a few drops of blood from a finger prick, the system generates lab-accurate results on the spot and data is reported in real time. The test menu includes up to 23 key biomarkers for screening and managing chronic diseases, such as diabetes and heart disease (e.g., HbA1c, Lipid Profile, eGFR). The HealthTab also has capabilities for bacterial and viral tests, such as strep and COVID-19. The HealthTab platform transforms pharmacies into community point-of-care diagnostic centers.
Directors
- David Hall NEC
- Hector Bremner CEO
- Kiki Smith CFO
- Rodger Seccombe CTO
- Alan Arnstein IND (52)
- David Farnfield IND
- Robert Sindelar IND (67)
- Last Annual
- December 31st, 2023
- Last Interim
- September 30th, 2024
- Incorporated
- May 30th, 2000
- Public Since
- July 31st, 2001
- Sector
- Software & IT Services
- Industry
- Technology
- Exchange
TSX Venture Exchange- Shares in Issue
- 101,289,664
- Address
- 1120 - 789 West Pender Street, VANCOUVER, V6C 1H2
- Web
- https://avricore.com/
- Phone
- +1 6047738943
- Auditors
- Manning Elliott LLP
Upcoming Events for AVCR
Q1 2025 Avricore Health Inc Earnings Release
Avricore Health Inc Annual Shareholders Meeting
Q2 2025 Avricore Health Inc Earnings Release
Similar to AVCR
01 Communique Laboratory
TSX Venture Exchange
Acceleware
TSX Venture Exchange
AGEDB Technology
TSX Venture Exchange
Aisix Solutions
TSX Venture Exchange
AnalytixInsight
TSX Venture Exchange
FAQ
What is the Avricore Health share price?
As of Today at 19:28 UTC, shares in Avricore Health are trading at CA$0.05. This share price information is delayed by 15 minutes.
How has the Avricore Health share price performed this year?
Shares in Avricore Health last closed at CA$0.05 and the price had moved by -67.86% over the past 365 days. In terms of relative price strength the Avricore Health share price has underperformed the Toronto Stock Exchange 300 Composite Index by -71.03% over the past year.
What are the analyst and broker recommendations for Avricore Health?
There is no consensus recommendation for this security.
Find out moreWhat is the Avricore Health dividend yield?
Avricore Health does not currently pay a dividend.
Does Avricore Health pay a dividend?
Avricore Health does not currently pay a dividend.
When does Avricore Health next pay dividends?
Avricore Health does not currently pay a dividend.
How do I buy Avricore Health shares?
To buy shares in Avricore Health you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Avricore Health?
As of the previous close price of CA$0.05, shares in Avricore Health had a market capitalisation of CA$4.56m.
Where are Avricore Health shares listed?
Here are the trading details for Avricore Health:
- Country of listing: Canada
- Exchange: CVE
- Ticker Symbol: AVCR
What kind of share is Avricore Health?
Based on an overall assessment of its quality, value and momentum Avricore Health is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Avricore Health share price forecast for 2025?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the Avricore Health share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Avricore Health. Over the past six months, its share price has underperformed the Toronto Stock Exchange 300 Composite Index by -72.95%.
As of the last closing price of CA$0.05, shares in Avricore Health were trading -66.51% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Avricore Health PE Ratio?
The Avricore Health PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CA$0.05.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Avricore Health?
Avricore Health's management team is headed by:
- David Hall - NEC
- Hector Bremner - CEO
- Kiki Smith - CFO
- Rodger Seccombe - CTO
- Alan Arnstein - IND
- David Farnfield - IND
- Robert Sindelar - IND